Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Upper Respiratory Drugs: Decongestants01:27

Upper Respiratory Drugs: Decongestants

1.3K
Decongestants are a class of medications used primarily to alleviate nasal congestion, a common symptom resulting from allergies, colds, sinusitis, and other upper respiratory tract infections. These drugs work by activating α-adrenergic receptors, constricting small blood vessels in the nasal membranes. This action results in the opening of clogged nasal passages, thereby facilitating sinus drainage and relieving congestion.
Most decongestants are readily available over-the-counter in...
1.3K
Drugs Used in Upper Respiratory Disorders: Overview01:16

Drugs Used in Upper Respiratory Disorders: Overview

1.0K
Upper respiratory tract disorders, including viral infections and allergic rhinitis, cause significant discomfort and disrupt daily life. Managing these conditions involves a variety of drugs, such as antihistamines, intranasal steroids, decongestants, antitussives, expectorants, and mucolytics. Specific examples of drugs in each category are provided.
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
1.0K
Epistaxis01:30

Epistaxis

740
Epistaxis, or nosebleeds, occurs when small, swollen blood vessels in the nasal mucous membrane rupture. Typically, the anterior septum is the primary site of occurrence.
Etiology
Possible causes of this condition include high blood pressure, trauma, low humidity, upper respiratory tract infections, allergies, foreign bodies, nasal inhalation of corticosteroids or illicit drugs, excessive use of decongestant nasal sprays, facial or nasal surgery, anatomic malformation, tumors, or systemic...
740
Allergic Reactions: Anaphylaxis01:30

Allergic Reactions: Anaphylaxis

183
Anaphylaxis is a severe, life-threatening hypersensitivity reaction mediated by Immunoglobulin E (IgE) antibodies. When IgE binds to allergens, it triggers the release of mediators– histamine, leukotrienes, and prostaglandins from mast cells and basophils. These mediators cause vasodilation, edema, and inflammation, leading to various symptoms.The primary allergens causing anaphylaxis include food items (e.g., peanuts, shellfish), drugs (e.g., penicillin, asparaginase, corticotropin,...
183
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

2.2K
Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
2.2K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

1.8K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Proposed changes to current definitions of ICHD-3 regarding headache and facial pain attributed to the disorder of the nose or paranasal sinuses.

Cephalalgia : an international journal of headache·2026
Same author

Meta-Analysis on the Harm of Systemic Glucocorticosteroids in Inflammatory Upper Airway Disease and Asthma: An EAACI Task Force.

Allergy·2026
Same author

In Reference to "Role of Previous Sinus Surgery Extent in Indication of Biologic Treatment for CRSwNP".

The Journal of craniofacial surgery·2026
Same author

Barrier dysfunction in nasal epithelium contributes to persistent inflammation in long COVID.

The Journal of allergy and clinical immunology·2025
Same author

Induction of IL-10-producing type 2 innate lymphoid cells by allergen immunotherapy is associated with clinical response.

Immunity·2025
Same author

Toward precision medicine: Inflammatory nasal epithelial transcriptomic profiles in long COVID.

The Journal of allergy and clinical immunology·2025

Related Experiment Video

Updated: Apr 7, 2026

Author Spotlight: Advancing Allergic Rhinitis Research with Multicolor Immunofluorescence
06:08

Author Spotlight: Advancing Allergic Rhinitis Research with Multicolor Immunofluorescence

Published on: September 22, 2023

2.9K

Capsaicin for non-allergic rhinitis.

Artur Gevorgyan1, Christine Segboer, Rob Gorissen

  • 1Department of Otorhinolaryngology, Academic Medical Centre, Meibergdreef 9, A2-234, 1105 Az, Amsterdam, Netherlands.

The Cochrane Database of Systematic Reviews
|July 15, 2015
PubMed
Summary

Capsaicin may be an effective treatment for non-allergic rhinitis, offering symptom improvement for up to 36 weeks. Further research is needed to confirm its benefits across different patient groups and application methods.

More Related Videos

Ex Vivo Release of Calcitonin Gene-Related Peptide from the Trigeminovascular System in Rodents
08:39

Ex Vivo Release of Calcitonin Gene-Related Peptide from the Trigeminovascular System in Rodents

Published on: May 16, 2022

3.2K
Advanced Glycation End-Products Sensitize Human Sensory-Like Neuron Cells to Capsaicin-Induced Calcium Influx
06:05

Advanced Glycation End-Products Sensitize Human Sensory-Like Neuron Cells to Capsaicin-Induced Calcium Influx

Published on: May 2, 2025

1.2K

Related Experiment Videos

Last Updated: Apr 7, 2026

Author Spotlight: Advancing Allergic Rhinitis Research with Multicolor Immunofluorescence
06:08

Author Spotlight: Advancing Allergic Rhinitis Research with Multicolor Immunofluorescence

Published on: September 22, 2023

2.9K
Ex Vivo Release of Calcitonin Gene-Related Peptide from the Trigeminovascular System in Rodents
08:39

Ex Vivo Release of Calcitonin Gene-Related Peptide from the Trigeminovascular System in Rodents

Published on: May 16, 2022

3.2K
Advanced Glycation End-Products Sensitize Human Sensory-Like Neuron Cells to Capsaicin-Induced Calcium Influx
06:05

Advanced Glycation End-Products Sensitize Human Sensory-Like Neuron Cells to Capsaicin-Induced Calcium Influx

Published on: May 2, 2025

1.2K

Area of Science:

  • Otolaryngology: Focuses on the ear, nose, and throat conditions.
  • Pharmacology: Investigates the therapeutic effects of capsaicin, the active compound in chili peppers.
  • Clinical Trials: Evaluates the efficacy of medical interventions through randomized controlled trials.

Background:

  • Non-allergic rhinitis affects 25-50% of rhinitis patients, presenting symptoms like nasal congestion and rhinorrhoea.
  • Current treatments include antihistamines, corticosteroids, and anticholinergics, with varying effectiveness.
  • Intranasal capsaicin is being explored as a potential treatment option for non-allergic rhinitis.

Purpose of the Study:

  • To evaluate the effectiveness of intranasal capsaicin for non-allergic rhinitis.
  • Comparisons were made against no therapy, placebo, other medications, or different capsaicin regimens.

Main Methods:

  • Systematic search of multiple databases for randomized controlled trials (RCTs) up to June 2015.
  • Included adult patients with idiopathic non-allergic rhinitis.
  • Four studies (302 participants) with follow-up periods of 4-38 weeks were analyzed.

Main Results:

  • Capsaicin demonstrated significant improvement in overall nasal symptoms compared to placebo (VAS scores improved by -3.34 to -3.73).
  • One study showed capsaicin was more likely to resolve symptoms than placebo (RR 3.17).
  • Capsaicin showed comparable or better results than budesonide for overall symptoms, but not individual ones.

Conclusions:

  • Intranasal capsaicin shows potential as a treatment for idiopathic non-allergic rhinitis, with sustained benefits up to 36 weeks.
  • Evidence quality is low to moderate, necessitating well-conducted RCTs for further validation.
  • Future research should explore capsaicin's efficacy in diverse non-allergic rhinitis types and severities.